Strumento inattivo

Azioni Occlutech Holding AG

Azioni

Durata

Periodo

Stile

Occlutech Holding AG continua i suoi progressi nello studio FDA statunitense OCCLUFLEX – Arruola il primo paziente in Europa	31/01/23	CI
Occlutech Holding AG nomina Jozef Bartunek come nuovo Chief Medical Officer	01/11/22	CI
Occlutech Holding AG nomina Jose De La Cortina come Chief Commercial Officer	06/09/22	CI

Occlutech Holding AG Continues its Progress in US FDA Study OCCLUFLEX – Enrolls First Patient in Europe	31/01/23
Occlutech Holding AG Appoints Jozef Bartunek as New Chief Medical Officer	01/11/22
Occlutech Holding AG Appoints Jose De La Cortina as Chief Commercial Officer	06/09/22
Occlutech Holding AG announced that it has received SEK 450 million in funding from AP Fonden 4, Carnegie Investment Bank AB	21/12/21
Occlutech Holding AG has withdrawn its IPO in the amount of SEK 963.8035 million.	28/09/21

Settore